注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Avidity Biosciences Inc是一家生物制药公司。该公司致力于提供一种称为抗体寡核苷酸结合物(AOC)的核糖核酸(RNA)疗法。该公司利用其AOC平台设计、设计和开发治疗学,将单克隆抗体(MAB)的特异性与寡核苷酸疗法的精确性结合起来,以针对以前无法用这种疗法治疗的疾病的根本原因。其主要候选产品AOC 1001旨在治疗强直性肌营养不良1型(DM1),这是一种罕见的单基因肌肉疾病。该公司推进和扩大的管道还包括AOC 1044,它是治疗杜氏肌营养不良症(DMD)的三个项目的领导者,以及AOC 1020,它旨在治疗面肩肱型肌营养不良症(FSHD)。AOC 1020由其单克隆抗体组成,其设计用于结合TfR1,并与靶向DUX4 mRNA的siRNA结合,作为静脉输注。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Christopher J. Kirk | 50 | - | Member of Scientific Advisory Board |
Anna M. Wu | - | - | Member of Scientific Advisory Board |
Jean Jinsun Kim | 48 | 2021 | Independent Director |
Richard A. Heyman | 65 | - | Member of Scientific Advisory Board |
Sarah Boyce | 50 | 2019 | President, CEO & Director |
Eran Nadav | 53 | - | Observer |
Ryan B. Corcoran | - | - | Member of Scientific Advisory Board |
Tamar Thompson | 48 | 2021 | Independent Director |
Frank P. McCormick | 74 | 2012 | Scientific Founder & Member of Scientific Advisory Board |
Troy Edward Wilson | 55 | 2012 | Co-Founder & Independent Chairman |
Arthur A. Levin | 70 | 2019 | Distinguished Scientist, Strategic Leader & Director |
Mark E. Davis | - | 2012 | Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers |
Noreen Roth Henig | 59 | 2019 | Independent Director |
Carsten Boess | 58 | 2020 | Independent Director |
Edward M. Kaye | 75 | 2019 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核